I think for me from all the research that we have seen, I think the EV103 cohort study was probably one of the most exciting ones, and I think when we talk with our patient community as well, we look at the data that have been presented there, we are looking to quite significant survival, right?
← all excerpts
Patient and Healthcare Professional Perspectives from ESMO 2022 on Bladder and Kidney Cancer: A Podcast.
1
—
—